Are entrepreneurial venture's innovation rates sensitive to investor complementary assets? Comparing biotech ventures backed by corporate and independent VCs

作者: Elisa Alvarez-Garrido , Gary Dushnitsky

DOI: 10.1002/SMJ.2359

关键词: Complementary assetsHomogeneous groupVenture capitalBiotechnologyCapital budgetingCorporate venture capitalLeverage (finance)Fda approvalBusiness

摘要: … publication and patent output compared to VC-backed peers. … , an investment from a CVC is associated with greater innovation … nurturing effect, by studying the effect of CVC backing not …

参考文章(61)
Jeffrey L. Furman, Fiona Murray, Scott Stern, More for the research dollar Nature. ,vol. 468, pp. 757- 758 ,(2010) , 10.1038/468757A
Isin Guler, Mauro F. Guillén, Home Country Networks and Foreign Expansion: Evidence from the Venture Capital Industry Academy of Management Journal. ,vol. 53, pp. 390- 410 ,(2010) , 10.5465/AMJ.2010.49389027
David H. Hsu, Rosemarie H. Ziedonis, Resources as dual sources of advantage: Implications for valuing entrepreneurial‐firm patents Strategic Management Journal. ,vol. 34, pp. 761- 781 ,(2013) , 10.1002/SMJ.2037
Harry J. Sapienza, When do venture capitalists add value Journal of Business Venturing. ,vol. 7, pp. 9- 27 ,(1992) , 10.1016/0883-9026(92)90032-M
Frank T. Rothaermel, Marie Thursby, The nanotech versus the biotech revolution: Sources of productivity in incumbent firm research Research Policy. ,vol. 36, pp. 832- 849 ,(2007) , 10.1016/J.RESPOL.2007.02.008
Richard C. Levin, Alvin K. Klevorick, Richard R. Nelson, Sidney G. Winter, Richard Gilbert, Zvi Griliches, Appropriating the Returns from Industrial Research and Development Brookings Papers on Economic Activity. ,vol. 1987, pp. 783- 832 ,(1987) , 10.2307/2534454